Clinical Trial: Impact of Oral Ibandronate 150 mg Monthly on Structural Properties of Bone in Postmenopausal Osteoporosis (SPIMOS-3D)

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Randomized Double-Blind Placebo-Controlled and Parallel Group Study to Evaluate the Impact of One Year Therapy With Monthly Oral Ibandronate 150 mg on Structural Properties of Bone in Efficacy:

To investigate changes of structural bone properties in vivo using 3DpQCT ("Xtreme" CT, Scanco) in monthly oral ibandronate therapy for women with postmenopausal osteoporosis.

Major structural bone parameters which determine bone strength and predict fracture risk earlier and more precisely are measurable in vivo by 3DpQCT.

Safety:

To assess the tolerability and safety of ibandronate therapy

Detailed Summary:
Sponsor: Charite University, Berlin, Germany

Current Primary Outcome: BV/TV and trab. Sp. measured by 3D pQCT device [ Time Frame: Baseline and after 3, 6, 9 and 12 months ]

Original Primary Outcome:

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Charite University, Berlin, Germany

Dates:
Date Received: January 3, 2006
Date Started: March 2006
Date Completion:
Last Updated: January 27, 2009
Last Verified: January 2009